Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-ICOS agonist monoclonal antibody BMS-986226

An agonistic monoclonal antibody that recognizes inducible T-cell co-stimulator (ICOS; CD278), with potential immunomodulating and antineoplastic activities. Upon administration, anti-ICOS agonist monoclonal antibody BMS-986226 targets and binds to ICOS expressed on certain T cells. This stimulates ICOS-mediated signaling, induces proliferation of ICOS-positive T cells, enhances cytotoxic T lymphocyte (CTL) survival and augments the CTL-mediated immune response against tumor cells. ICOS, a T-cell-specific, CD28-superfamily co-stimulatory molecule and immune checkpoint protein, is normally expressed on certain activated T cells and plays a key role in the proliferation and activation of T cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-ICOS BMS-986226
anti-inducible T-cell co-stimulator BMS-986226
Code name:BMS 986226
BMS-986226
BMS986226
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search